Advaxis' John Rothman to Present Phase I Data at the World Vaccine Congress 2007.

Conference to be Held October 9(th) in Lyon, France

NEW BRUNSWICK, N.J. -- John Rothman, Advaxis' (OTCBB: ADXS.OB) Vice President of Clinical Development, will be a speaker at this year's World Vaccine Congress 2007, to be held on October 9th at 4:55 CET (10:55PM ET) at the Palais des Congr[c]s de Lyon in Lyon, France. Dr. Rothman will be disclosing key findings that resulted from the recent Phase I/II trial of Advaxis' lead vaccine, Lovaxin C, a modified Listeria-based live vaccine for the treatment of cervical cancer. Furthermore, Dr. Rothman will also discuss, "Bacterial Vectors Presenting an Immunological Advantage Over Virus-Based Vaccines."

"The World Vaccine Congress Lyon 2007 is a international forum where leading researchers with breakthrough technologies get to present their work and learn from each other," says Rothman about the 3 day-long conference that is to include interactive panels and high-level case studies. "I am pleased that Advaxis is included among the distinguished group of leaders in this space."

Dr. Rothman is expected to discuss the advantages of Listeria bacterial vector systems in evoking a safe and effective therapeutic immune response and will include information on the pre-clinical data demonstrating how this technology induces anti-tumor immunity. Rothman is expected to discuss Phase I/II study data relating to both the safety of the current live cervical cancer vaccine as well as the use of this agent as an efficacious therapy.

In April, Advaxis completed the enrollment and dosing in patients diagnosed with advanced, recurrent, or progressive cervical cancer in its Phase I/II clinical trial of Lovaxin C. Assessments made by an independent safety panel prior to beginning each higher dosage group found that Lovaxin C, a modified Listeria-based live vaccine is safe, even in very ill end-stage cancer patients.

The trial was designed to test four different doses in cohorts of five patients. Side effects experienced by patients included a flu like syndrome comprised of transient mild-moderate fever and chills and transient nausea, all of which usually resolved within hours of dosing in the lower dosage groups. At highest dose tested an effective dose ceiling was determined, thus enabling the determination of future safe and effective dosage regimens. The study was conducted in Israel, Serbia, and Mexico.

About Advaxis

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria-based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical, head, and neck cancers. Further Listeria vaccines in development target breast, ovarian, and lung cancers. Advaxis has entered a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.